Introduction
============

Primary tumor sidedness has prognostic and predictive value in metastatic colorectal cancer (CRC), and has thus emerged as a new biomarker ([@b1-or-43-06-1853],[@b2-or-43-06-1853]). Several analyses revealed that right-sided colorectal cancer (RCRC) exhibited significantly worse prognosis than left-sided colorectal cancer (LCRC) ([@b3-or-43-06-1853]--[@b5-or-43-06-1853]), and anti-EGFR therapy clearly benefitted patients with LCRC, whereas patients with RCRC derived limited benefit ([@b6-or-43-06-1853]--[@b10-or-43-06-1853]). However, the mechanism of the differences between RCRC and LCRC has not been fully elucidated.

RCRC and LCRC have different clinicopathological and molecular characteristics. RCRC is generally characterized by being more common in women, and associated with Lynch syndrome, sessile serrated adenoma/polyp (SSA/P), mitogen-activated protein kinase signaling, microsatellite instability-high (MSI-H), deficiency of mismatch repair genes, CpG island methylation, and *KRAS* and *BRAF* V600E mutations ([@b11-or-43-06-1853]--[@b15-or-43-06-1853]). LCRC is more common in men, and associated with familial adenomatous polyposis syndrome, traditional serrated adenoma (TSA), chromosomal instability, *ERBB1* and *ERBB2* amplifications, and *APC, p53*, and *NRAS* mutations ([@b11-or-43-06-1853]--[@b15-or-43-06-1853]). Based on these clinicopathological and molecular differences, primary tumor sidedness is considered to be associated with prognosis and efficacy of targeted therapy.

Mutations in *RNF43* have been reported in several solid tumors, such as colorectal ([@b16-or-43-06-1853]--[@b18-or-43-06-1853]), gastric ([@b19-or-43-06-1853]), pancreatic ([@b20-or-43-06-1853]), ovarian ([@b21-or-43-06-1853]), and endometrial ([@b22-or-43-06-1853]) cancers. *RNF43* encodes a RING-type E3 ubiquitin ligase, and the protein is predicted to contain a transmembrane domain, a protease-associated domain, an ectodomain, and a cytoplasmic RING domain ([@b23-or-43-06-1853]). Expression of RNF43 results in increased ubiquitination of frizzled receptors, and an alteration in their subcellular distribution, resulting in reduced surface levels of these receptors. RNF43 is considered to negatively regulate WNT signaling, and functions as a tumor suppressor. Loss of RNF43 results in decrease or lack of degradation of frizzled receptors, with an enhancement of WNT signaling. In cancer cells, inactivation of RNF43 through *RNF43* mutation is one of the causes of permanent activation of the WNT signaling pathway ([@b23-or-43-06-1853]).

Serrated neoplasia, which is a precancerous lesion of CRC, is associated with primary tumor sidedness: SSA/P is associated with RCRC, while TSA is associated with LCRC ([@b24-or-43-06-1853]). Recently, several studies revealed the importance of *RNF43* mutation in the serrated neoplasia pathway, i.e., *RNF43* mutation was associated with serrated neoplasia pathway such as SSA/P ([@b25-or-43-06-1853]) and TSA ([@b26-or-43-06-1853],[@b27-or-43-06-1853]). Moreover, it has been reported that *RNF43* mutation in serrated neoplasia is associated with *BRAF* V600E mutation ([@b17-or-43-06-1853]), which is recognized as one of the characteristics of RCRC and a significant negative prognostic factor in metastatic CRC ([@b1-or-43-06-1853],[@b2-or-43-06-1853]). Collectively, it was surmised that *RNF43* mutation may play different roles in RCRC and LCRC. Recently, it has been reported that *RNF43* mutations contribute to tumorigenesis in RCRC ([@b18-or-43-06-1853]). However, to date, clinical significance of *RNF43* mutation have not been fully investigated according to primary tumor sidedness. It was hypothesized that the clinical significance of *RNF43* mutations differ between RCRC and LCRC. To test this hypothesis, the clinicopathological characteristics and survival outcome of patients with *RNF43* mutation in RCRC and LCRC were investigated.

Materials and methods
=====================

### Patients

This retrospective study was approved by the Ethics Committee of the Niigata University School of Medicine, and performed in accordance with the Helsinki Declaration (G2015-0816). All methods were performed in accordance with the relevant guidelines and regulations, and written informed consent was obtained from the patients. A total of 201 Japanese patients (117 male and 84 female patients; median age 65 years old; range, 30--94 years) with stage I--IV CRC according to AJCC, 7th edition ([@b28-or-43-06-1853]) who underwent a primary tumor resection between January 2009 and December 2015 at the Niigata University Medical and Dental Hospital or Niigata Cancer Center Hospital were included in this study. The median follow-up period was 34 months (range, 1--92 months). Patients diagnosed with adenocarcinoma were included. Patients under 18 years old were excluded. Patients with synchronous double primary CRC or other active concurrent malignant diseases, inflammatory bowel disease or familial adenomatous polyposis were excluded. No patient had received neoadjuvant chemoradiation. Typically, chemotherapy was administered according to the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines ([@b29-or-43-06-1853]). Adjuvant chemotherapy, including fluorouracil or its derivatives ± oxaliplatin, was usually administered in stage III patients for six months. For patients with unresectable metastatic diseases, molecular targeted therapy was administered according to RAS mutational status.

In the present analysis, *RNF43* mutational prevalence, spectrum and frequency between our cohort and TCGA samples were compared. The mutation information for the TCGA CRC-sequenced samples (n=489) was obtained from the cBioPortal (<https://www.cbioportal.org/>) ([@b30-or-43-06-1853]) to assess mutation frequency.

### Comprehensive genomic sequence analysis of primary tumors

As previously described ([@b15-or-43-06-1853],[@b31-or-43-06-1853]--[@b34-or-43-06-1853]), formalin-fixed, paraffin-embedded (FFPE) samples were used for next-generation sequencing (NGS), and genetic alterations, including *RNF43*, were evaluated. Briefly, hematoxylin and eosin-stained sections were used to assess tumor content, to ensure that \>50% tumor content was present. Where applicable, unstained sections were macro-dissected to enrich for tumor content. DNA was extracted using a BioStic FFPE Tissue DNA Isolation Kit (Mo Bio Laboratories, Inc.). All sample preparation, NGS, and bioinformatics analysis were performed in a CLIA/CAP-accredited laboratory (KEW, Inc.). DNA fragment libraries (50--150 ng) were prepared and enriched for the 415-gene panel with CANCERPLEX Version 3.0 (KEW, Inc.). An average 500X sequencing depth was achieved using Illumina MiSeq or NextSeq platforms. A proprietary bioinformatics platform and knowledge base were used to process genomic data and to identify multiple genomic abnormalities, including SNPs, small indels, copy number variation, and translocations. An allelic fraction threshold of 10% was used for SNPs and indels, and thresholds of \>2.5-fold for gain, and 0.5-fold for loss, were used. Tumors were assessed for the presence of MSI on the basis of an extended loci panel. In addition to the Bethesda panel ([@b35-or-43-06-1853]), a collection of 950 regions consisting of tandem repeats of one, two or three nucleotides with a minimum length of 10 bases was used ([@b31-or-43-06-1853]). Tumor mutational burden was calculated as the number of non-synonymous mutations per megabase of sequence in the panel (panel size=1.3 Mb).

### RNF43 status and clinicopathological characteristics

The 201 patients were classified into *RNF43* wild-type or *RNF43* mutant-type; moreover, *RNF43* mutant-type were subdivided into right-sided *RNF43* mutant-type or left-sided *RNF43* mutant-type according to primary tumor sidedness. Primary tumor location was determined by operative findings. Cancer in the cecum, ascending colon, hepatic flexure, or transverse colon was classified as RCRC; while cancer in the splenic flexure, descending colon, sigmoid colon, rectosigmoid, or rectum was classified as LCRC ([@b15-or-43-06-1853]).

### Statistical analysis

Statistical analyses were performed with IBM SPSS Statistics 22 (IBM Japan, Inc.). Fisher\'s exact test was used to evaluate the associations between *RNF43* status and clinicopathological characteristics. To clarify clinicopathological characteristics which were independently associated with *RNF43* mutation, factors with a P-value of \<0.10 in univariate analyses were entered into a multivariate analysis. Logistic analysis was performed to identify factors that were independently associated with *RNF43* mutation. Five-year overall survival (OS) rates were estimated using the Kaplan-Meier method. The log-rank test was used to assess for significant differences between subgroups. P-values \<0.05 were considered to indicate statistically significant differences.

Results
=======

### Alteration of RNF43 in Japanese CRC

To date, there has been no studies regarding genetic alterations of *RNF43* among Japanese CRC patients; hence, the genetic alterations of *RNF43* were evaluated and compared with The Cancer Genome Atlas (TCGA) data (<https://www.cbioportal.org/>). *RNF43* nonsense/frameshift mutation was more frequently observed in RCRC compared with LCRC in both of the Japanese cohorts (P\<0.001; [Figs. 1A](#f1-or-43-06-1853){ref-type="fig"} and [2A](#f2-or-43-06-1853){ref-type="fig"}) and TCGA samples (P=0.042; [Figs. 1B](#f1-or-43-06-1853){ref-type="fig"} and [2B](#f2-or-43-06-1853){ref-type="fig"}).

### Clinicopathological characteristics in relation to RNF43 mutation status

The 415-gene panel assessment successfully detected genetic alterations in all 201 patients. The 415-gene panel assessment revealed that 174 (87%) patients were *RNF43* wild-type and 27 (13%) patients were *RNF43* mutant-type. *RNF43* mutant-type was significantly associated with age (≥65; P=0.003), females (P=0.006), absence of venous invasion (P=0.003), absence of distant metastasis (P=0.021), *BRAF* V600E mutation (P\<0.001), and MSI-H (P\<0.001), and multivariate analysis revealed that age (≥65), absence of venous invasion, and *BRAF* V600E mutation were independently associated with *RNF43* mutation ([Table I](#tI-or-43-06-1853){ref-type="table"}).

### Genetic alterations of the MAPK pathway other than BRAF V600E mutation in RNF43 mutant-type

Seventeen of the 27 patients with *RNF43* mutant-type had no *BRAF* V600E mutation. Nine of the 17 patients had mutations other than *BRAF* V600E in the MAPK pathway: 6 patients had *KRAS* mutation, 3 patients had *BRAF* non-V600E mutation; however, no patient had *NRAS* mutation.

### RNF43 mutant-type according to primary tumor sidedness

Among the 27 patients with *RNF43* mutation, 12 patients were right-sided *RNF43* mutant-type and 15 left-sided *RNF43* mutant-type. As revealed in [Fig. 2A](#f2-or-43-06-1853){ref-type="fig"}, 11 of the 12 right-sided *RNF43* mutant-type had nonsense/frameshift mutations, while 14 of 15 left-sided *RNF43* mutant-type had missense mutations. Right-sided *RNF43* mutant-type was significantly associated with histopathological grade 3 (P=0.008), lymphatic invasion (P=0.021), *APC* wild (P=0.003), *BRAF* V600E mutation (P\<0.001), MSI-H (P=0.008), and *RNF43* nonsense/frameshift mutation (P\<0.001) compared with left-sided *RNF43* mutant-type ([Table II](#tII-or-43-06-1853){ref-type="table"}; [Fig. 2A](#f2-or-43-06-1853){ref-type="fig"}).

### Overall survival in relation to RNF43 status and primary tumor sidedness

In 90 patients with stage I--III disease, *RNF43* mutation was not a significant prognostic factor for 5 year OS ([Fig. 3A](#f3-or-43-06-1853){ref-type="fig"}), and primary tumor sidedness was not associated with *RNF43* mutant-type.

In 111 patients with stage IV disease, *RNF43* mutation was not a significant prognostic factor for OS ([Fig. 3B](#f3-or-43-06-1853){ref-type="fig"}). However, when *RNF43* mutant-type was subdivided into right-sided *RNF43* mutant-type or left-sided *RNF43* mutant-type according to primary tumor sidedness, right-sided *RNF43* mutant-type exhibited significantly worse overall survival than *RNF43* wild-type and left-sided *RNF43* mutant-type (P=0.001 and P=0.023, respectively; [Fig. 3C](#f3-or-43-06-1853){ref-type="fig"}). Regarding variants of *RNF43* mutations, all right-sided *RNF43* mutant-type had nonsense mutation (R145X) or frameshift mutation (P192fs, S262fs, G659fs), while all left-sided *RNF43* mutant-type had missense mutations (T58S, W200C, R221W, R519Q; [Table III](#tIII-or-43-06-1853){ref-type="table"}). All the four right-sided *RNF43* mutant-type were older in age (≥65), females, and *BRAF* V600E mutant-type. Three of four patients with right-sided *RNF43* mutation had two or more metastatic sites; conversely, all five patients with left-sided *RNF43* mutation had one metastatic site. While all patients with right-sided *RNF43* mutant-type succumbed to their cancer, three of the five patients with left-sided *RNF43* mutant-type were alive at the final follow-up ([Table III](#tIII-or-43-06-1853){ref-type="table"}).

Discussion
==========

This analysis has three main findings regarding *RNF43* mutations in CRC. Firstly, most of *RNF43* mutations in RCRC were nonsense or frameshift mutations, while those in LCRC were missense mutations. Secondly, right-sided *RNF43* mutant-type was significantly associated with histopathological grade 3 and *BRAF* V600E mutation. Thirdly, right-sided *RNF43* mutant-type exhibited significantly worse OS than left-sided *RNF43* mutant-type. These results indicated that right-sided *RNF43* mutant-type is one of the clinically important subtypes in CRC, and *RNF43* nonsense/frameshift mutations, along with *BRAF* V600E mutation, may be a possible cause of worse prognosis of RCRC.

In this analysis, it was revealed that 13% of the Japanese CRC patients in this study had *RNF43* mutations, while 9% of patients in the TCGA cohort had *RNF43* mutations ([@b36-or-43-06-1853],[@b37-or-43-06-1853]). Recently, several studies have revealed the role of *RNF43* mutations in the serrated neoplastic pathway of CRC. Hashimoto *et al* reported that WNT pathway gene mutations, including *RNF43* mutation, were more common in SSA/P with dysplasia than in SSA/P without dysplasia, and suggested that WNT pathway gene mutations are involved in the development of dysplasia in SSA/P ([@b25-or-43-06-1853]). Tsai *et al* reported the incidence of *RNF43* mutation in SSA/P (10%) and TSA (28%), and stated that *RNF43* mutation is an early and specific molecular aberration in the serrated neoplasia pathway ([@b26-or-43-06-1853]). Yan *et al* reported *RNF43* germline and somatic mutation along with *BRAF* V600E mutation in the serrated neoplasia pathway ([@b16-or-43-06-1853]). However, the clinical significance of *RNF43* mutation has not been fully elucidated; hence, the clinicopathological characteristics of *RNF43* mutation were investigated, with a focus on the association between *RNF43* mutation and primary tumor sidedness.

To the best of our knowledge, this is the first study which investigated the survival outcome of *RNF43* mutant-type according to primary tumor sidedness in CRC. Previous studies have reported that hotspot mutations, mainly frameshift (R117fs and G659fs), are found in microsatellite-instable SSA/P and CRC ([@b23-or-43-06-1853]). In this analysis, 201 patients with stage I--IV CRC were investigated, and it was revealed that 11 out of 12 right-sided *RNF43* mutant-type had nonsense/frameshift mutations, while 14 out of 15 left-sided *RNF43* mutant-type had missense mutations. Although RNF43 protein expression was not investigated, *RNF43* nonsense/frameshift mutation may be a cause of loss of function of RNF43 protein. It is speculated that *RNF43* nonsense/frameshift mutation can become a cause of stimulation of the WNT signaling pathway, and is associated with the aggressive tumor biology of RCRC.

Approximately 5 to 9% patients with CRC have *BRAF* V600E mutation, and *BRAF* V600E mutation is recognized as a distinct molecular subtype of CRC ([@b1-or-43-06-1853],[@b2-or-43-06-1853]). Multiple studies have revealed that the *BRAF* V600E mutation is associated with poor prognosis in metastatic CRC ([@b38-or-43-06-1853],[@b39-or-43-06-1853]), as well as poor response to anti-EGFR therapy in later lines of therapy ([@b40-or-43-06-1853],[@b41-or-43-06-1853]). In the present study, it was revealed that 10 out of 12 right-sided *RNF43* mutant-type had *BRAF* V600E mutation. It is surmised that both *RNF43* and *BRAF* V600E mutations are important for the tumor biology of right-sided *RNF43* mutant-type; i.e., *RNF43* nonsense/frameshift mutation, along with *BRAF* V600E mutation, induce enhancement of both the WNT and MAPK signaling pathways, resulting in a worse prognosis in right-sided *RNF43* mutant-type.

In stage IV disease, it was revealed that right-sided *RNF43* mutant-type exhibited significantly worse OS than left-sided *RNF43* mutant-type, and all patients with right-sided *RNF43* mutant-type succumbed to their cancer. These results suggest that right-sided *RNF43* mutant-type is a distinct subtype that has potentially worse prognosis. We consider that *RNF43* mutation should be treated differently according to primary tumor sidedness, since the clinicopathological characteristics and survival outcomes differ between right-sided *RNF43* mutant-type and left-side *RNF43* mutant-type. Thus, how should this dismal molecular subtype 'right-sided *RNF43* mutant-type' be treated? At present, right-sided *RNF43* mutant-type may be treated the same as *BRAF* V600E mutant-type ([@b1-or-43-06-1853],[@b2-or-43-06-1853]), since it was revealed that most right-sided *RNF43* mutant-type cases had *BRAF* V600E mutation in this analysis. In the future, WNT signaling plus BRAF inhibitors may be applied for right-sided *RNF43* mutant-type ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT02278133).

This analysis has some limitations. First, this retrospective analysis was performed at two institutions. Second, it included a small number of patients; specifically, the study had only 90 patients with Stage I--III disease. Future analysis should include a larger number of patients with CRC from large-scale multi-institutional studies or a cancer registry. It is speculated that the microbiome may be associated with tumor carcinogenesis and phenotype, and certain bacteria may be associated with genetic alterations in CRC. For example, it has been reported that *Fusobacterium nucleatum* is enriched in tumor tissue of MSI-H CRC ([@b42-or-43-06-1853],[@b43-or-43-06-1853]). Although we do not have data linking the microbiome to the results of our study at present, we plan to investigate the relationship between genetic alteration of right-sided CRC and the patient microbiome. Collectively, this analysis is important for clarifying the clinicopathological characteristics and prognosis of *RNF43* mutant-type according to primary tumor sidedness, and facilitating the research of future treatment strategies.

In conclusion, clinicopathological characteristics and survival outcome of patients with *RNF43* mutation may differ between RCRC and LCRC. In RCRC, *RNF43* mutation may be a small, but distinct molecular subtype that is associated with aggressive tumor biology along with *BRAF* V600E mutation. Future preclinical and clinical studies may have to focus on *RNF43* mutation to improve survival outcome in CRC.
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The location and frequency of *RNF43* mutations according to primary tumor sidedness. (A) Japanese samples; (B) TCGA samples. TCGA, The Cancer Genome Atlas.
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Oncoprint of right-sided *RNF43* mutant-type and left-sided *RNF43* mutant-type. (A) Japanese samples; (B) TCGA samples. TCGA, The Cancer Genome Atlas.
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###### 

Overall survival according to *RNF43* mutation status and primary tumor sidedness. (A) Overall survival of *RNF43* wild-type and *RNF43* mutant-type in stage I--III colorectal cancer. (B) Overall survival of *RNF43* wild-type and *RNF43* mutant-type in stage IV colorectal cancer. (C) Overall survival of *RNF43* wild-type, right-sided *RNF43* mutant-type, and left-sided *RNF43* mutant-type in stage IV colorectal cancer.
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###### 

*RNF43* gene status and other clinicopathological characteristics in colorectal cancer.

                              *RNF43* gene status             Multivariate                          
  --------------------------- --------------------- --------- -------------- ---------------------- -------------
  Age (years)                                                                                       
    \<65                      94 (46)               6 (3)     **0.003**      1                      
    ≥65                       80 (40)               21 (10)                  3.04 (1.03--8.90)      **0.042**
  Sex                                                                                               
    Male                      108 (53)              9 (4)     **0.006**                             
    Female                    66 (33)               18 (9)                                          
  Location                                                                                          
    Right side                44 (22)               12 (6)    0.062                                 
    Left side                 130 (65)              15 (7)                                          
  Tumor size (mm)                                                                                   
    \<50                      75 (37)               13 (6)    0.679                                 
    ≥50                       99 (49)               14 (7)                                          
  pT category                                                                                       
    T1, 2                     20 (10)               4 (2)     0.539                                 
    T3, 4                     154 (76)              23 (11)                                         
  Histopathological grading                                                                         
    G1, 2                     128 (63)              19 (9)    0.816                                 
    G3                        46 (23)               8 (4)                                           
  Lymphatic invasion                                                                                
    Absence                   65 (32)               14 (7)    0.203                                 
    Presence                  109 (54)              13 (6)                                          
  Venous invasion                                                                                   
    Absence                   35 (17)               13 (6)    **0.003**      1                      
    Presence                  139 (69)              14 (7)                   0.18 (0.06--0.52)      **0.002**
  pN category                                                                                       
    N0                        49 (24)               10 (5)    0.362                                 
    N1, 2                     125 (62)              17 (8)                                          
  cM category                                                                                       
    M0                        72 (36)               18 (9)    **0.021**                             
    M1                        102 (51)              9 (4)                                           
  *APC*                                                                                             
    Wild-type                 29 (14)               9 (4)     0.061                                 
    Mutant                    145 (72)              18 (9)                                          
  *KRAS*                                                                                            
    Wild-type                 105 (52)              21 (10)   0.091                                 
    Mutant                    69 (34)               6 (3)                                           
  *BRAF* V600E                                                                                      
    Wild-type                 171 (85)              17 (9)    **\<0.001**    1                      
    Mutant                    3 (1)                 10 (5)                   45.68 (9.76--213.81)   **\<0.001**
  MSI                                                                                               
    MSI-H                     7 (3)                 8 (4)     **\<0.001**                           
    MSS                       167 (84)              19 (9)                                          

Fisher\'s exact test. CI, confidence interval; MSI, microsatellite instability; MSI-H, microsatellite instability-high. Bold indicates P\<0.05.

###### 

Clinicopathological characteristics according to primary tumor sidedness in *RNF43* mutant colorectal cancer.

                              Primary tumor sidedness             
  --------------------------- ------------------------- --------- -------------
  Age (years)                                                     
    \<65                      1 (4)                     5 (18)    0.182
    ≥65                       11 (40)                   10 (37)   
  Sex                                                             
    Male                      3 (11)                    6 (22)    0.683
    Female                    9 (33)                    9 (33)    
  Tumor size (mm)                                                 
    \<50                      5 (18)                    8 (29)    0.704
    ≥50                       7 (26)                    7 (26)    
  pT category                                                     
    T1, 2                     1 (4)                     3 (11)    0.605
    T3, 4                     11 (40)                   12 (44)   
  Histopathological grading                                       
    G1, 2                     5 (18)                    14 (52)   **0.008**
    G3                        7 (26)                    1 (4)     
  Lymphatic invasion                                              
    Absence                   3 (11)                    11 (40)   **0.021**
    Presence                  9 (33)                    4 (15)    
  Venous invasion                                                 
    Absence                   4 (15)                    9 (33)    0.252
    Presence                  8 (30)                    6 (22)    
  pN category                                                     
    N0                        3 (11)                    7 (26)    0.424
    N1, 2                     9 (33)                    8 (30)    
  cM category                                                     
    M0                        8 (30)                    10 (37)   0.999
    M1                        4 (15)                    5 (18)    
  *APC*                                                           
    Wild-type                 8 (30)                    1 (4)     **0.003**
    Mutant                    4 (15)                    14 (52)   
  *KRAS*                                                          
    Wild-type                 11 (40)                   10 (37)   0.182
    Mutant                    1 (4)                     5 (18)    
  *BRAF* V600E                                                    
    Wild-type                 2 (7)                     15 (55)   **\<0.001**
    Mutant                    10 (37)                   0 (0)     
  MSI                                                             
    MSI-H                     7 (26)                    1 (4)     **0.008**
    MSS                       5 (18)                    14 (52)   
  Variants of *RNF43*                                             
    Nonsense or frameshift    11 (40)                   1 (4)     **\<0.001**
    Missense                  1 (4)                     14 (52)   

Fisher\'s exact test. MSI, microsatellite instability; MSI-H, microsatellite instability-high. Bold indicates P\<0.05.

###### 

Clinical course of *RNF43* mutant-type patients with Stage IV disease.

  Genetic alteration   Age   Sex   Primary tumor location   *KRAS* status   *BRAF* status     MSI status   Tumor mutational burden   Initial metastatic sites          Treatment                                                                                                                    Survival status (months after primary tumor resection)
  -------------------- ----- ----- ------------------------ --------------- ----------------- ------------ ------------------------- --------------------------------- ---------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------
  S262fs               71    F     Right                    Wild            V600E             MSS          19                        Liver, Lung, Spleen, Peritoneum   R2 resection (Primary) → FOLFOX + Bmab → FOLFIRI                                                                             Dead (8 months)
  R145X                66    F     Right                    Wild            26_34del, V600E   MSS          19                        Para-aortic lymph node            R0 resection (Primary and Para-aortic LN) → Lung, LN recurrence → FOLFOX + Bmab                                              Dead (13 months)
  P192fs               80    F     Right                    Wild            V600E             MSS          18                        Lung                              R2 resection (Primary) → XELOX + Bmab                                                                                        Dead (20 months)
  G659fs               78    F     Right                    Wild            V600E             MSI-H        48                        Liver, Peritoneum                 R2 resection (Primary) → FOLFOX + Pmab                                                                                       Dead (8 months)
  R519Q                35    F     Left                     Wild            Wild              MSS          10                        Liver                             R2 resection (Primary) → FOLFOX + Bmab → R0 resection (Liver) → Liver and lung recurrence → FOLFOX + Bmab → FOLFIRI + Pmab   Alive (44 months)
  R519Q                86    M     Left                     Wild            Wild              MSS          11                        Lung                              R2 resection (Primary) → Xeloda → XELOX + Bmab → IRIS + Pmab                                                                 Alive (45 months)
  W200C                70    F     Left                     Wild            D594G             MSS          19                        Liver                             R2 resection (Primary) → R0 resection (Liver) → Liver recurrence → R0 resection (Liver)                                      Alive (40 months)
  R221W                77    M     Left                     Wild            Wild              MSS          12                        Liver                             R2 resection (Primary) → XELOX → IRIS → Pmab                                                                                 Dead (11 months)
  T58S                 75    F     Left                     Wild            Wild              MSS          11                        Liver                             R2 resection (Primary) → XELOX + Bmab → R0 resection (Liver) → Lung recurrence                                               Dead (41 months)

FOLFOX = 5FU + Leucovorin + Oxaliplatin; FOLFIRI = 5FU + Leucovorin + Irinotecan; XELOX = Xeloda + Oxaliplatin; IRIS = Irinotecan + S-1. Bmab, Bevacizumab; Pmab, Panitumumab; MSS, microsatellite stable.
